2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Granuloma Annulare: new trials by email Literature Review of Granuloma Annulare trials Research Report on Granuloma Annulare
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tyrosine Kinase 2 (TYK2) for GA and CS Deucravacitinib - Sarcoidosis, Granuloma Annulare | Phase 2 | Withdrawn | Yale University | 2025-03-01 | 2025-04-29 | |
| Janus Kinase Inhibition in Granuloma Annulare Abrocitinib 200 mg - Granuloma Annulare | Phase 2 | Completed | William Damsky | 10 | 2023-10-27 | 2026-10-07 |
| Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix UVB Irradiation - Keloid, Scleroderma, Localized | Phase 1 / Phase 2 | Completed | University of Michigan | 33 | 2002-08-01 | 2015-05-01 |
Acne Keloid (1) · Cicatrix (1) · Inhibition, Psychological (1) · Keloid (1) · Sarcoidosis (1) · Scleroderma, Diffuse (1) · Scleroderma, Localized (1)
Collagen Diseases (3) · Connective Tissue Diseases (3) · Granuloma (3) · Necrobiotic Disorders (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Acneiform Eruptions (1) · Behavior (1) · Fibrosis (1) · Folliculitis (1) · Hair Diseases (1) · Hemic and Lymphatic Diseases (1) · Hypersensitivity (1)
abrocitinib (1) · deucravacitinib (1)
University of Michigan (1) · William Damsky (1) · Yale University (1)
United States (3)
John J Voorhees, MD (1) · William Damsky, M.D. (1) · William Damsky, MD (1)